Last reviewed · How we verify
NCT07107152
Effect of Static vs. Conversational AI-Generated Messages on Colorectal Cancer Screening Intent: a Randomized Controlled Trial
NA trial testing single GPT generated message in Colorectal Cancer Control and Prevention in 915 participants. Completed in 21 June 2025.
21 June 2025
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 915 |
| Start date | 11 June 2025 |
| Primary completion | 21 June 2025 |
| Estimated completion | 21 June 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- single GPT generated message
- AI Chatbot
- Expert-Written Patient Materials
Conditions studied
- Colorectal Cancer Control and Prevention — all drugs for Colorectal Cancer Control and Prevention →
Sponsor
University of Pennsylvania
Who can join
Adults 45 to 75, any sex, with Colorectal Cancer Control and Prevention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to assess whether messages generated by a large language model (LLM), including both static and conversational formats, can increase colorectal cancer (CRC) screening intentions among U.S. adults aged 45-75 who have never completed CRC screening. The main questions it aims to answer are: Do personalized, AI-generated messages increase the self-reported likelihood of completing a stool-based CRC screening test within 12 months? Do they also increase intent to undergo colonoscopy screening within 12 months? Researchers will compare four groups: (1) no message control, (2) expert-written patient education materials, (3) a single AI-generated persuasive message, and (4) a motivational interviewing-style AI chatbot. These comparisons will help assess whether a conversational format offers added benefit over static AI or expert-generated content. Participants will: Be randomly assigned to one of the four study arms Spend at least 3 minutes reading or interacting with their assigned material Complete pre- and post-intervention surveys assessing intent to receive CRC screening Receive messages tailored to their self-reported demographics, including age, political ideology, gender, education, community setting (urban, rural, suburb), self-reported health, and the last time they saw their PCP
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07107152
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer Control and Prevention
Currently open trials in the same condition.
- NCT06974500 — Implementation of an Efferent Loop Stimulation Protocol Prior to Ileostomy Closure at La Paz University Hospital · recruiting
- NCT06629051 — 6-year Follow-up Data After the Berberine Intervention Trial · recruiting
- NCT06775951 — Appropriateness of Colonoscopy Indication: an Evaluation of the Clinical and Economic Impact. · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07107152 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 7 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07107152.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing